IL6R and autoimmune disease: Combined with previous reports about the usefulness of neutralizing anti-IL-6R monoclonal antibody to treat autoimmune diseases via inhibiting Th17 responses[32-34], our finding suggests a novel strategy for treating CHB patients, e.g. inhibiting IL-6R expression by anti-IL-6R antibodies to restrain Th17-mediated liver damage.